Sanofi (SNY) Shareholder Senzar Asset Management LLC Has Decreased Stake as Shares Rose

July 18, 2017 - By Michael Collier

Senzar Asset Management Llc decreased its stake in Sanofi (SNY) by 13.97% based on its latest 2016Q4 regulatory filing with the SEC. Senzar Asset Management Llc sold 200,400 shares as the company’s stock rose 14.25% with the market. The hedge fund held 1.23M shares of the major pharmaceuticals company at the end of 2016Q4, valued at $49.91M, down from 1.43 million at the end of the previous reported quarter. Senzar Asset Management Llc who had been investing in Sanofi for a number of months, seems to be less bullish one the $121.27 billion market cap company. The stock increased 0.04% or $0.02 on July 17, reaching $48.18. About shares traded. Sanofi SA (ADR) (NYSE:SNY) has risen 26.96% since July 18, 2016 and is uptrending. It has outperformed by 10.26% the S&P500.

Senzar Asset Management Llc, which manages about $442.00M and $377.08 million US Long portfolio, upped its stake in Halozyme Therapeutics Inc (NASDAQ:HALO) by 674,900 shares to 1.23 million shares, valued at $12.11M in 2016Q4, according to the filing. It also increased its holding in Allergan Plc by 100,200 shares in the quarter, for a total of 158,700 shares, and has risen its stake in Aerie Pharmaceuticals Inc (NASDAQ:AERI).

Wall Street await Sanofi SA (ADR) (NYSE:SNY) to release earnings on August, 4. Analysts forecast EPS of $0.78, up exactly $0.04 or 5.41 % from 2014’s $0.74 EPS. The expected SNY’s profit could reach $1.96 billion giving the stock 15.44 P/E in the case that $0.78 earnings per share is reported. After posting $0.76 EPS for the previous quarter, Sanofi SA (ADR)’s analysts now forecast 2.63 % EPS growth.

More recent Sanofi SA (ADR) (NYSE:SNY) news were published by: Investorplace.com which released: “Think Sanofi SA (ADR) (SNY) Stock When You Think Big Pharma” on December 09, 2016. Also Investorplace.com published the news titled: “3 Stocks to Watch on Monday: Tesla Inc (TSLA), Sanofi SA (ADR) (SNY) and …” on April 03, 2017. Investorplace.com‘s news article titled: “5 Reasons Why Sanofi SA (ADR) (SNY) is a Good Stock to Buy Now” with publication date: April 12, 2017 was also an interesting one.

Sanofi SA (ADR) (NYSE:SNY) Ratings Coverage

Among 10 analysts covering Sanofi-aventis Sa (NYSE:SNY), 3 have Buy rating, 1 Sell and 6 Hold. Therefore 30% are positive. Sanofi-aventis Sa has $56 highest and $50.0 lowest target. $53’s average target is 10.00% above currents $48.18 stock price. Sanofi-aventis Sa had 16 analyst reports since October 15, 2015 according to SRatingsIntel. Bernstein downgraded the shares of SNY in report on Monday, November 9 to “Mkt Perform” rating. The stock of Sanofi SA (ADR) (NYSE:SNY) earned “Neutral” rating by JP Morgan on Wednesday, April 12. The stock of Sanofi SA (ADR) (NYSE:SNY) earned “Buy” rating by Berenberg on Thursday, September 8. The company was upgraded on Tuesday, September 13 by BNP Paribas. HSBC downgraded the shares of SNY in report on Friday, April 7 to “Reduce” rating. Berenberg downgraded Sanofi SA (ADR) (NYSE:SNY) on Thursday, May 11 to “Hold” rating. The firm has “Overweight” rating given on Thursday, May 12 by Barclays Capital. The rating was maintained by JP Morgan on Friday, April 21 with “Neutral”. The company was downgraded on Tuesday, May 3 by HSBC. Argus Research initiated Sanofi SA (ADR) (NYSE:SNY) rating on Thursday, April 6. Argus Research has “Buy” rating and $50.0 target.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.